This is Nick Hodge's latest comment on Lexagene.
LexaGene (TSX-V: LXG)(OTC: LXXGF), fresh off a C$2.8 million raise, has announced that Dr. Jame Marsden has joined its advisory board to steer its penetration of the food industry. Marsden just retired from Chipotle, where he led a multi-year effort to rebuild the company’s reputation after multiple food illness episodes. He has served as an adviser to the White House on food safety and nutrition issues. Marsden says, "The food industry has been looking for the right genomics-based technology to adopt to help make their products safer. Lexagene's technology has the speed, breadth of detection, sensitivity and ease of use that the industry is demanding, and it is affordable enough for widespread adoption. Lexagene has an opportunity to set the standard for genomics-based pathogen detection in the food industry, and I look forward to helping them achieve this goal." The food angle is on top of the veterinary angle that I’ve been covering the past few months. LexaGene is a buy as it trades at C$0.67, and is due for a run toward $1.00.
